StockNews.com Initiates Coverage on Tonix Pharmaceuticals (NASDAQ:TNXP)

Analysts at StockNews.com assumed coverage on shares of Tonix Pharmaceuticals (NASDAQ:TNXP) in a research note issued on Sunday. The brokerage set a “sell” rating on the stock.

Separately, Dawson James started coverage on Tonix Pharmaceuticals in a report on Wednesday, February 28th. They issued a “buy” rating and a $3.00 target price for the company.

Tonix Pharmaceuticals Price Performance

Shares of NASDAQ TNXP opened at $0.19 on Friday. The company has a debt-to-equity ratio of 0.06, a current ratio of 2.53 and a quick ratio of 1.81. The stock has a fifty day moving average price of $0.25 and a 200 day moving average price of $0.36. Tonix Pharmaceuticals has a 1-year low of $0.12 and a 1-year high of $3.31. The company has a market cap of $16.39 million, a PE ratio of -0.02 and a beta of 2.16.

Tonix Pharmaceuticals (NASDAQ:TNXP) last issued its quarterly earnings results on Monday, April 1st. The company reported ($0.86) earnings per share for the quarter. The company had revenue of $3.78 million during the quarter, compared to analysts’ expectations of $3.95 million. Sell-side analysts forecast that Tonix Pharmaceuticals will post -3.18 EPS for the current year.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Tonix Pharmaceuticals stock. Armistice Capital LLC increased its stake in shares of Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) by 160.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,770,000 shares of the company’s stock after purchasing an additional 2,320,000 shares during the quarter. Armistice Capital LLC owned approximately 14.09% of Tonix Pharmaceuticals worth $1,519,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 82.26% of the company’s stock.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.